- Company
- Sale of Atozet generics exceeds its orignial in 1 year
- by Kim, Jin-Gu Apr 29, 2022 05:42am
- The combination drug market for dyslipidemia treatment using the atorvastatin+ ezetimibe combination has increased twofold with the sudden growth of its generics. Moreover, the market share of the generics exceeded that of the original in Q1 of this year. The rapid expansion of the market last year is interpreted to be due to more than 100 co
- Company
- LG Chem will jointly sell Nesp & Regpara with Kyowa Kirin
- by Kim, Jin-Gu Apr 29, 2022 05:41am
- LG Chem announced on the 28th that it has signed a contract with Kyowa Kirin Korea to jointly sell two drugs, Nesp(Darbepoetin Alfa) and Regpara (Cinacalcet Hydrochloride)' in Korea. LG Chem is in charge of sales at the clinics level, and Kyowa Kirin Korea is in charge of sales at the general hospital level. Nesp is a continuous hematopoietic
- Company
- Immunotherapy Opdivo reattempts reimb in gastric cancer
- by Eo, Yun-Ho Apr 28, 2022 06:07am
- The cancer immunotherapy Opidvo is again attempting to receive insurance benefits for its gastric cancer indication. According to industry sources, ONO Pharma Korea and BMS Korea’s PD-1 inhibitor immunotherapy drug ‘Opdivo (nivolumab)’ will be presented for deliberation by the Cancer Disease Deliberation Committee of the Health Insuran
- Company
- Sales of SGLT-2 diabetes drugs increased by 15%
- by Apr 28, 2022 06:06am
- The SGLT-2 inhibitor market, which surpassed 150 billion won in annual prescriptions last year, also grew 15% in the first quarter, surpassing 40 billion won in quarterly prescriptions. single and combination drugs have grown evenly. According to UBIST, a pharmaceutical market research firm, on the 28th, the total amount of outpatient prescri
- Company
- Who will follow SK Bio with its homegrown COVID-19 vaccine?
- by Kim, Jin-Gu Apr 28, 2022 06:06am
- The marketing authorization for SK Bioscience’s homegrown COVID-19 vaccine 'GBP510' is nearing approval. If the drug is approved within the first half of the year as planned, GBP510 will become the first homegrown vaccine to be ever approved. With the developer of the first vaccine set, who will be the No.2 and No.3 in line is gaining
- Company
- Novartis' anticancer drug/Rx division will be merged
- by Eo, Yun-Ho Apr 27, 2022 06:04am
- A change is expected in Novartis' subsidiary. Above all, the anticancer drug division and the Rx division, which have been operated independently, will be integrated. According to related industries, Novartis' Asia-Pacific Regional Headquarters has already been appointed as a representative of the integrated corporation. As a result, corporat
- Company
- Additional formulations of Abbvie’s Skyrizi were approved
- by Eo, Yun-Ho Apr 27, 2022 06:04am
- The approval of an additional formulation of the IL-23 inhibitor ' Skyrizi' has increased the drug’s versatility in the field of plaque psoriasis. On the 22nd, Abbvie Korea announced that the Ministry of Food and Drug Safety additionally approved its Skyrizi Prefilled Syringe 150mg and Prefilled Pen 150mg formulations of its IL-23 inhibi
- Company
- Benefit of Pfizer's Cibinqo is applied
- by Eo, Yun-Ho Apr 26, 2022 06:12am
- Another JAK inhibitor aims to enter the atopic dermatitis insurance benefit right. According to related industries, Pfizer Korea recently submitted an application for benefits of Cibinqo, a new drug for JAK1. As Lilly's Olumiant and AbbVie's Rinvoq are expected to be applied in May. Cibinqo was approved in Korea in November last year when
- Company
- RET targeted therapy Retevmo opens era of precision medicine
- by Apr 26, 2022 06:12am
- Lilly Korea’s RET targeted therapy Retevmo(selpercatinib) has landed in Korea. The drug is expected to become a new treatment option in RET fusion-positive patients with non-small-cell lung cancer and thyroid cancer. Lilly Korea held an online press conference to celebrate the approval of Retevmo on the 25th. Professor Min Hee Hong of Oncolo
- Company
- President-elect Yoon visits SK Bioscience HQ
- by Kim, Jin-Gu Apr 26, 2022 06:12am
- President-elect Suk-yeol Yoon visited SK Bioscience headquarters in Seongnam, Gyeonggi-do, and promised “We will spare no effort in the development of vaccines so no one can say they could not develop vaccines due to lack of money.” Transition team chair Cheol-soo Ahn and members of the Social Welfare subcommittee of the transition team ac
